US industry hails House committee hard line on user fee bill
This article was originally published in Clinica
Executive Summary
US industry association AdvaMed has applauded the House energy and commerce health committee for its passage late last week of the user fee bill (MDUFMA), and especially for its removal of a proposal to limit the pre-emptive effect of the FDA's device-specific actions. This would have potentially created hundreds of standards for medical technology manufacturers, said AdvaMed president and CEO Stephen Ubl.